A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
INTRODUCTION: Tirzepatide, a glucagon-like peptide-1 receptor agonist (GLP1RA) and glucose-dependent insulinotropic-peptide (GIP), has shown efficacy regarding weight-loss. METHODS: Systematic review and network meta-analysis of randomized controlled…
Oral delivery of peptides and proteins has been pursued for over a century due to its noninvasive nature. Despite sustained innovation across multiple technological generations-such as enteric coatings, enzyme inhibitors, permeation enhancers, nanopa…
BACKGROUND & AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) is a risk factor for progressive hepatic fibrosis and cirrhosis. The role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the treatment of patients with MASH with f…
Semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has attracted significant global attention for its appetite-suppressing and weight-loss effects. Approved for pediatric use in child…
PURPOSE: To evaluate the real-world impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on health-related quality of life (HRQoL) and metabolic outcomes in adults with type 2 diabetes and obesity. METHODS: We conducted a multicenter prosp…
AIMS: Acute myocardial infarction (AMI) is among the leading causes of mortality in patients with type 2 diabetes (T2DM). This study evaluated whether initiation of glucagon-like peptide-1 receptor agonists (GLP1RAs) post-AMI improves cardiovascular…
AIMS: The aim of this systematic review and meta-analysis was to evaluate the effect of GLP-1RAs on functional walking distance and the risk of major adverse limb events (MALE) or lower extremity amputation (LEA) in people with type 2 diabetes and pe…
AIMS: We aimed at comparing different approved strategies (obesity management medications-OMM, endoscopic bariatric procedures-EBP, and metabolic bariatric surgery-MBS) with lifestyle intervention/placebo/no therapy (LSI/Pbo/NT) for the treatment of…
AIMS/HYPOTHESIS: Simultaneous control of HbA, lipid profile, BP and body weight is essential for preventing chronic complications of type 2 diabetes. Glucagon-like peptide-1 (GLP-1)-based therapies improve all these variables but whether the dual GLP…
Pediatric cardiomyopathy is a major cause of diastolic heart failure; yet, its mechanisms remain unclear. Global myocardial transcriptomic and blood lipidomic profiling revealed a distinct metabolic signature of diastolic dysfunction marked by dysreg…
: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced the treatment of type 2 diabetes mellitus (T2DM), yet their association with cancer risk remains subject of ongoing research. Chronic pancreatitis (CP) is a well-established risk f…
We present 2 case reports of the benefits of the subcutaneous once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy semaglutide in adolescents with type 1 diabetes (T1D) complicated by obesity. Two female individuals (17 and 12 years…
Sublingual delivery of peptide therapeutics is hindered by mucosal barriers and poor bioavailability. This study aimed to evaluate and optimize sublingual administration of TE-8105, a long-acting dual fatty acid-conjugated GLP-1 receptor agonist that…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for conditions beyond type 2 diabetes, including psoriasis and hidradenitis suppurativa. Despite this, little is known about their dermatologic safety profi…
INTRODUCTION: Mitochondrial diabetes is rare and typically treated with dietary intervention and oral hypoglycaemic agents. Most require insulin. Novel treatments are available but are not well-characterised. PRESENTATION: A 16-year-old adolescent gi…
Spinal epidural lipomatosis (SEL) is a rare cause of lumbar canal stenosis, typically linked to obesity or corticosteroid use. Severe cases often require decompression. We report a 48-year-old man with chronic low back pain and morbid obesity (153 kg…
AIMS: Once-weekly (OW) insulins represent a promising strategy to reduce injection burden and improve adherence in type 2 diabetes management. This meta-analysis aimed to quantify pooled effect sizes for key biological and clinical outcomes, integrat…
BACKGROUND: Psoriasis is a chronic inflammatory skin disease often associated with obesity and metabolic dysfunction, which may worsen disease severity. Glucagon-like peptide-1 receptor agonists, such as semaglutide, have shown metabolic and anti-inf…
Cardiovascular disease (CVD) remains the leading cause of global mortality, with pathophysiological alterations such as heart failure with preserved ejection fraction, diabetic cardiomyopathy, and atherosclerotic cardiomyopathy representing major ris…